Patrick J. McEnany - 15 Jul 2026 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Reporting relationship: Director, Chairman of Board of Directors
Issuer ticker: CPRX
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:15:48 UTC
Prior SEC filing: 30 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. McEnany

Key filing fact

Patrick J. McEnany filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 17 Jul 2026.

Key facts

This page summarizes Patrick J. McEnany's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
11 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 17 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 30 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000929985 Primary reporting owner

MCENANY PATRICK J

Relationship: Director, Chairman of Board of Directors
Address: 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES
Signature: /s/ Patrick J. McEnany
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CPRX transaction

Common Stock, par value $0.001 per share

Disposed to Issuer

Transaction value
Shares: -4,171,559
Change %: -100%
Price: $31.50^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -740,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 740,000
Exercise price: $4.64
Footnotes: F3, F5

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -400,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $3.42
Footnotes: F3, F5

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -270,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 270,000
Exercise price: $7.07
Footnotes: F3, F5

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -272,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 272,000
Exercise price: $18.59
Footnotes: F3, F5

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -73,810
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 73,810
Exercise price: $14.15
Footnotes: F3, F6

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -43,591
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,591
Exercise price: $21.12
Footnotes: F3, F6

CPRX transaction Derivative

Options to purchase common stock

Disposed to Issuer

Transaction value
Shares: -34,921
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,921
Exercise price: $22.77
Footnotes: F3, F6

CPRX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -3,534
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,534
Exercise price
Footnotes: F2, F4, F6

CPRX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -3,552
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,552
Exercise price
Footnotes: F2, F4, F6

CPRX transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -10,540
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,540
Exercise price
Footnotes: F2, F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Patrick J. McEnany is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.

Footnote F4

In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.

Footnote F5

Each Option was fully vested.

Footnote F6

Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.